Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as a strong investment opportunity by hedge funds, with multiple analysts raising price targets and maintaining positive ratings on the stock [1][2][3] Group 1: Analyst Ratings and Price Targets - Bernstein reiterated a Hold rating on Bristol-Myers Squibb with a price target of $58.00 as of February 10 [1] - Morgan Stanley raised its price target from $37 to $40 while maintaining an Underweight rating, citing that the 2026 revenue and EPS guidance exceeded consensus due to a higher-than-expected Eliquis guide [1] - BofA increased its price target from $64 to $68 and maintained a Buy rating, noting that the company delivered fiscal Q4 and FY26 guidance beats, emphasizing that Bristol-Myers is a "pipeline story" [2] - Guggenheim raised its price target from $62 to $72, maintaining a Buy rating and increasing the odds of success for key drugs iber/mezi and milvexian to 90% [3] Group 2: Company Overview - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [4]

Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 10 Most Profitable Undervalued Stocks to Buy, with multiple firms raising their price targets following positive earnings reports and promising pipeline developments [1][3][5]. Price Target Updates - Guggenheim raised its price target on BMY to $72 from $62, citing a significant increase in the estimated probability of success for key drugs [1]. - Bank of America increased its price target to $68 from $64, highlighting strong fourth-quarter results and positive fiscal 2026 guidance [3]. - Wells Fargo raised its price target to $60 from $55, indicating potential upside if the growth portfolio exceeds current expectations [4]. - Citi lifted its price target to $64 from $60, maintaining a Neutral rating while emphasizing the importance of pipeline execution for future share upside [5]. Financial Performance - Bristol-Myers reported fourth-quarter revenue of $12.5 billion, surpassing the consensus estimate of $12.28 billion, indicating strong performance and momentum in its growth portfolio [6]. Pipeline and Future Outlook - The company is expected to have a data-rich 2026, with multiple pivotal pipeline readouts anticipated in the latter half of the year, which could significantly impact its growth trajectory [6]. - Analysts noted that the positive Phase 3 read-across from Bayer's SSP data helps to mitigate risks associated with the milvexian opportunity [3].